CAMBRIDGE, Mass., May 6, 2024
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC),
today announced that, effective May 1,
2024, the Compensation Committee of Blueprint Medicines'
Board of Directors granted non-qualified stock options to purchase
an aggregate of 6,400 shares of its common stock and an aggregate
of 3,200 restricted stock units (RSUs) to two new employees under
Blueprint Medicines' 2020 Inducement Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Blueprint Medicines, as an inducement
material to such individual's entering into employment with
Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq
Listing Rules.
The options have an exercise price of $94.86 per share, which is equal to the closing
price of Blueprint Medicines' common stock on May 1, 2024. Each option will vest as to 25% of
the shares underlying such option on the first anniversary of the
grant date and as to an additional 1/48th of the shares underlying
the option monthly thereafter, in each case, subject to each
such employee's continued employment on each vesting date. Each RSU
will vest as to 25% of the shares underlying the RSU award on the
first anniversary of the grant date and as to an additional 25% of
the shares underlying the RSU award annually thereafter, subject to
each such employee's continued employment on each vesting date. The
options and RSUs are subject to the terms and conditions of
Blueprint Medicines' 2020 Inducement Plan, and the terms and
conditions of the stock option and RSU agreement covering the
grant.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated
biopharmaceutical company that invents life-changing medicines. We
seek to alleviate human suffering by solving important medical
problems in two core focus areas: allergy/inflammation and
oncology/hematology. Our approach begins by targeting the root
causes of disease, using deep scientific knowledge in our core
focus areas and drug discovery expertise across multiple
therapeutic modalities. We have a track record of success with two
approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib),
which we are bringing to patients with systemic mastocytosis (SM)
in the U.S. and Europe. Leveraging
our established research, development, and commercial capability
and infrastructure, we now aim to significantly scale our impact by
advancing a broad pipeline of programs ranging from early science
to advanced clinical trials in mast cell diseases including SM and
chronic urticaria, breast cancer and other solid tumors. For more
information, visit www.BlueprintMedicines.com and follow
us on X (formerly Twitter; @BlueprintMeds)
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302136893.html
SOURCE Blueprint Medicines Corporation